Full Press Release Details
Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference.
GLUE
Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
Key Takeaway: Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
Price reaction · baseline $22.65 (2021-09-29 close) · hit after-hours · clean, no other GLUE news in the window
day 0 close · peak
-1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+67%
120-day peak, hindsight
Typical move
13.3%
average across 9 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
MRT-2359
Phase 2 · Castration-Resistant Prostate Cancer (CRPC)